BALAXI PHARMA Latest Share Price (BALAXI)
TODAY IN ONE LINE
BALAXI edged up 0.7% on above-average volume (217323.5x avg), in line with Nifty's -0.3% move, supported by recent strong earnings.
With a market cap of ₹128.8 Cr., it trades at a P/E of 12.63. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BALAXI PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 417.7% and Profit up 203.5%
- ●Reasonable ValuationTrading at a moderate P/E of 12.6x
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.25x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Price MomentumStock underperformed, dropping 25.3% over 1Y
- ●Earnings DeclineEPS (TTM) has contracted by 58.4% YoY
- ●Poor Capital ReturnsLow ROE of 3.9%
- ●Rising Receivables vs SalesReceivables grew 91.4% outpacing sales growth of 21.2%
Latest BALAXI PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
BALAXI PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BALAXI PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
BALAXI PHARMA trades at a P/E of 12.63×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BALAXI PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BALAXI PHARMA — derived from the latest tape, not yesterday's close.
BALAXI PHARMA last traded at ₹23.39 with an intraday range of ₹22.75–₹24.69 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹23.39| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 28.35 | +4.96 | +21.21% |
| R3 | 26.41 | +3.02 | +12.91% |
| R2 | 25.55 | +2.16 | +9.23% |
| R1 | 24.47 | +1.08 | +4.62% |
| PIVOT | 23.61 | 0.22 | 0.94% |
| CURRENT | 23.39 | — | — |
| S1 | 22.53 | -0.86 | -3.68% |
| S2 | 21.67 | -1.72 | -7.35% |
| S3 | 20.59 | -2.80 | -11.97% |
| S4 | 18.65 | -4.74 | -20.27% |
BALAXI is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹22.75–₹23.4
Trading Inside opening range
BALAXI PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BALAXI PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
BALAXI PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹128.8 Cr. and reported EPS of ₹0.24.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 293 | 270 ▼ 7.7% |
| Sales Growth YoY %Derived | 21.25% | -7.65% |
| Other Income | -4 | 3 ▲ 175.9% |
| Total Income | 289 | 273 ▼ 5.5% |
| 166 | 151 ▼ 8.9% | |
| Gross ProfitDerived | 127 | 119 ▼ 6.0% |
| Gross Margin %Derived | 43.36% | 44.16% |
| 90 | 111 ▲ 23.6% | |
| EBITDA (Operating Profit)Derived | 37 | 9 ▼ 77.1% |
| OPM %Derived | 12.72% | 3.16% |
| 5 | 6 ▲ 25.4% | |
| Profit Before Tax (PBT) | 29 | 5 ▼ 81.5% |
| 4 | 4 ▲ 7.7% | |
| Effective Tax %Derived | 12.55% | 73.23% |
| Total Profit for Period | 25 | 1 ▼ 94.3% |
| Net Profit (Owner's PAT)Derived | 25 | 1 ▼ 94.3% |
| Net Profit Margin %Derived | 8.57% | 0.52% |
| PAT Growth YoY %Derived | 1,150.28% | -94.35% |
| Earnings Per Share (EPS ₹) | 4.54 | 0.26 ▼ 94.3% |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 3 | 16 ▲ 512.9% |
| Total Expenses (incl. D&A & Interest) | 260 | 268 ▲ 2.9% |
| Material Cost % of RevenueDerived | 56.64% | 55.84% |
| Employee Cost % of RevenueDerived | 11.87% | 14.14% |
| Other Cost % of RevenueDerived | 18.77% | 26.86% |
| Interest Coverage (x)Derived | 12.04x | 1.63x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 46 | 231 ▲ 406.9% | 279 ▲ 20.8% | 336 ▲ 20.4% | 241 ▼ 28.3% | 293 ▲ 21.2% | 270 ▼ 7.7% | |
| Sales Growth YoY %Derived | — | 406.95% | 20.77% | 20.42% | -28.28% | 21.25% | -7.65% | |
| Other Income | 3 | 2 ▼ 20.8% | 5 ▲ 123.2% | 3 ▼ 47.0% | -3 ▼ 200.4% | -4 ▼ 40.4% | 3 ▲ 175.9% | |
| Total Income | 48 | 234 ▲ 382.1% | 284 ▲ 21.7% | 339 ▲ 19.2% | 239 ▼ 29.6% | 289 ▲ 21.0% | 273 ▼ 5.5% | |
34 | 172 ▲ 412.7% | 196 ▲ 13.6% | 202 ▲ 3.5% | 129 ▼ 36.4% | 166 ▲ 28.8% | 151 ▼ 8.9% | ||
| Gross ProfitDerived | 12 | 59 ▲ 390.9% | 84 ▲ 41.6% | 134 ▲ 59.9% | 113 ▼ 16.0% | 127 ▲ 12.6% | 119 ▼ 6.0% | |
| Gross Margin %Derived | 26.42% | 25.58% | 29.99% | 39.83% | 46.67% | 43.36% | 44.16% | |
6 | 17 ▲ 180.2% | 34 ▲ 100.3% | 77 ▲ 130.7% | 66 ▼ 15.0% | 90 ▲ 36.1% | 111 ▲ 23.6% | ||
| EBITDA (Operating Profit)Derived | 6 | 42 ▲ 598.7% | 50 ▲ 18.4% | 57 ▲ 12.6% | 47 ▼ 17.3% | 37 ▼ 20.4% | 9 ▼ 77.1% | |
| OPM %Derived | 13.30% | 18.33% | 17.97% | 16.81% | 19.37% | 12.72% | 3.16% | |
0 | 0 ▲ 4045.3% | 1 ▲ 110.3% | 2 ▲ 244.5% | -35 ▼ 1632.5% | 5 ▲ 114.0% | 6 ▲ 25.4% | ||
| Profit Before Tax (PBT) | 9 | 44 ▲ 399.6% | 55 ▲ 23.0% | 57 ▲ 4.4% | 2 ▼ 96.5% | 29 ▲ 1322.6% | 5 ▼ 81.5% | |
3 | 6 ▲ 123.6% | 7 ▲ 10.9% | 11 ▲ 59.7% | 4 ▼ 59.8% | 4 ▼ 18.2% | 4 ▲ 7.7% | ||
| Effective Tax %Derived | 31.21% | 13.97% | 12.59% | 19.25% | 218.44% | 12.55% | 73.23% | |
| Total Profit for Period | 6 | 38 ▲ 524.8% | 48 ▲ 25.0% | 46 ▼ 3.6% | -2 ▼ 105.2% | 25 ▲ 1150.3% | 1 ▼ 94.3% | |
| Net Profit (Owner's PAT)Derived | 6 | 38 ▲ 524.8% | 48 ▲ 25.0% | 46 ▼ 3.6% | -2 ▼ 105.2% | 25 ▲ 1150.3% | 1 ▼ 94.3% | |
| Net Profit Margin %Derived | 13.38% | 16.49% | 17.06% | 13.66% | -0.99% | 8.57% | 0.52% | |
| PAT Growth YoY %Derived | — | 524.79% | 24.96% | -3.56% | -105.19% | 1,150.28% | -94.35% | |
| Earnings Per Share (EPS ₹) | 1.22 | 7.45 ▲ 510.7% | 9.53 ▲ 27.9% | 9.03 ▼ 5.2% | -0.44 ▼ 104.9% | 4.54 ▲ 1131.8% | 0.26 ▼ 94.3% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% | 5 ▲ 0.0% | 5 ▲ 1.8% | 5 ▲ 7.0% | 6 ▲ 1.3% | 6 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | -1 ▼ 3642.4% | 1 ▲ 158.3% | 6 ▲ 998.2% | -5 ▼ 185.1% | 3 ▲ 152.8% | 16 ▲ 512.9% | |
| Total Expenses (incl. D&A & Interest) | 40 | 189 ▲ 378.2% | 230 ▲ 21.5% | 282 ▲ 22.8% | 237 ▼ 16.1% | 260 ▲ 9.9% | 268 ▲ 2.9% | |
| Material Cost % of RevenueDerived | 73.58% | 74.42% | 70.01% | 60.17% | 53.33% | 56.64% | 55.84% | |
| Employee Cost % of RevenueDerived | 4.60% | 3.66% | 4.46% | 8.61% | 11.35% | 11.87% | 14.14% | |
| Other Cost % of RevenueDerived | 8.52% | 3.59% | 7.56% | 14.42% | 15.96% | 18.77% | 26.86% | |
| Interest Coverage (x)Derived | — | 3,214.89x | 350.93x | 109.57x | 26.61x | 12.04x | 1.63x |
BALAXI PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at BALAXI PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
BALAXI PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BALAXI PHARMA.
Our AI distills the core fundamental drivers supporting BALAXI PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BALAXI PHARMA's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Attractive P/E ratio of 12.63x suggests undervaluation relative to current earnings capacity.
Conservative debt-to-equity ratio of 0.0022 indicates fortress-like balance sheet and financial stability.
Substantial cash position of ₹388.49 Cr provides operational flexibility and strategic optionality.
5-year EBITDA CAGR of 36.77% reflects strong historical operational efficiency and growth trajectory.
Diversified product portfolio across pharmaceuticals, FMCG, and hardware reduces revenue concentration risk.
Key Risks.
Latest quarterly EPS declined 93.89% YoY, signaling severe recent profitability deterioration.
TTM EPS declined 58.44% YoY despite positive revenue, indicating acute margin compression challenges.
Quarterly net profit collapsed 95.50% to ₹0.29 Cr, raising immediate operational viability concerns.
Operating margin compressed to 3.40% TTM from 13.41% (5-year average), suggesting structural cost pressures.
FII holdings eased from 18.57% to 3.50%, reflecting significant foreign investor confidence erosion.
Flip Conditions.
Valuation risk. a P/E above 16 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
BALAXI PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BALAXI PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BALAXI PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BALAXI PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BALAXI PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BALAXI PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BALAXI PHARMA stood at 63.4% of traded volume, against a 20-day average of 79.1%.
BALAXI PHARMA announcements: results, concalls, ratings, M&A.
Filings BALAXI PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BALAXI PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 78 documents below.
Updates
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the…
General Updates
Balaxi Pharmaceuticals Limited has informed the Exchange about the receipt of WHO-GMP Certification for Company's Pharmaceutical Formulation…
Shareholders meeting
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Proceedings of the 83rd Annual General Meeting held on 24th August, 2026
Copy of Newspaper Publication
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
Copy of Newspaper Publication
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
BALAXI PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BALAXI PHARMA has declared, sequenced by announce and record date.
BALAXI PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BALAXI PHARMA: business, sector, key facts.
What BALAXI PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BALAXI PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BALAXI.
Balaxi Pharmaceuticals Limited is an international wholesale distributor of a diverse range of products, primarily focused on serving markets in Africa, the Caribbean Islands, and Latin America. The company's core business centers around the pharmaceutical sector, where it offers a broad selection of medications targeting various therapeutic areas. This includes crucial treatments for common ailments and infections such as antibiotics, analgesics (painkillers), and anti-malarial drugs, alongside other pharmaceutical products.
Beyond pharmaceuticals, Balaxi Pharmaceuticals Limited extends its distribution network to encompass fast-moving consumer goods (FMCG) and builders' hardware. In the FMCG realm, the company's offerings include essential items such as biscuits and toothpaste. The inclusion of these products demonstrates a strategy to diversify its portfolio and cater to a broader consumer base in the regions it serves. This multi-product approach likely allows the company to leverage its established distribution network for greater efficiency and market penetration.
Established in 1942 and headquartered in Hyderabad, India, Balaxi Pharmaceuticals Limited has a long history in international trade. The company operates as a subsidiary of Balaxi Overseas Private Limited, indicating a larger corporate structure with potentially broader resources and strategic direction. The name change from Balaxi Ventures Limited to Balaxi Pharmaceuticals Limited in October 2020 reflects a strategic focus on the pharmaceutical sector while maintaining its commitment to diversified product offerings within its established international markets.
In summary, Balaxi Pharmaceuticals Limited's business model is built upon a foundation of international wholesale distribution, skillfully navigating the complexities of supplying diverse product categories to various markets across Africa, the Caribbean, and Latin America. The company leverages its long-standing presence and established network to efficiently reach its target customer base, demonstrating a robust and adaptable business strategy in a dynamic international environment.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BALAXI PHARMA (BALAXI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BALAXI PHARMA (BALAXI)?
The current share price of BALAXI PHARMA (BALAXI) is ₹23.39. Today, the stock has gained by ₹0.15 (0.65%), trading in a range of ₹22.75 to ₹24.69. The stock opened at ₹23.40 with a trading volume of 39,705 shares.
02Is BALAXI PHARMA stock a good investment for long-term?
BALAXI PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹128.8 Cr., P/E ratio of 12.63, ROE of 3.87%, and ROCE of 4.42%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BALAXI PHARMA stock?
The 52-week high price of BALAXI PHARMA (BALAXI) is ₹47.71, while the 52-week low is ₹15.20. Currently trading at ₹23.39, the stock is 53.88% above its 52-week low and 50.97% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BALAXI PHARMA stock at the current price?
Whether to buy BALAXI PHARMA stock at ₹23.39 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.63 and P/B ratio of 0. Today's performance shows a gain of 0.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BALAXI PHARMA and when is the next dividend?
BALAXI PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹23.39, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of BALAXI PHARMA?
BALAXI PHARMA's key financial metrics include: P/E Ratio: 12.63, P/B Ratio: 0, ROE: 3.87%, ROCE: 4.42%, Dividend Yield: 0%, EPS: ₹0.24, Book Value: ₹45.12, and Debt-to-Equity: 0.25. The company's market cap stands at ₹128.8 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is BALAXI PHARMA stock performing today in the market?
BALAXI PHARMA stock opened at ₹23.40 and is currently trading at ₹23.39, showing a gain of ₹0.15 (0.65%). The intraday high is ₹24.69 and low is ₹22.75. The trading volume stands at 39,705 shares, indicating moderate market participation today.
08What is the P/E ratio of BALAXI PHARMA and what does it indicate?
BALAXI PHARMA has a Price-to-Earnings (P/E) ratio of 12.63, which means investors are willing to pay 12.63 for every ₹1 of earnings. With an EPS of ₹0.24, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about BALAXI PHARMA (BALAXI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.